• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

FDA Approved Treatments: Topical Ruxolitinib and Vitiligo Management

Author(s):

Andrea Rosik, PA-C

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts in this video
3 experts in this video
Related Content
Plasma Protein Analysis Identifies New Drug Targets for Atopic Dermatitis
December 6th 2024

Plasma Protein Analysis Identifies New Drug Targets for Atopic Dermatitis

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Dermatology Times Hosts Inaugural Horizons in Advanced Practice Meeting
December 4th 2024

Dermatology Times Hosts Inaugural Horizons in Advanced Practice Meeting

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

November 2024 Atopic Dermatitis and Vitiligo Supplement Recap
November 28th 2024

November 2024 Atopic Dermatitis and Vitiligo Supplement Recap

Defining Treatment Options for Managing Chronic Atopic Dermatitis: Part 3
November 26th 2024

Defining Treatment Options for Managing Chronic Atopic Dermatitis: Part 3

© 2024 MJH Life Sciences

All rights reserved.